CN102872110A - Houttuynoid D在治疗乳腺癌药物中的应用 - Google Patents
Houttuynoid D在治疗乳腺癌药物中的应用 Download PDFInfo
- Publication number
- CN102872110A CN102872110A CN2012104193381A CN201210419338A CN102872110A CN 102872110 A CN102872110 A CN 102872110A CN 2012104193381 A CN2012104193381 A CN 2012104193381A CN 201210419338 A CN201210419338 A CN 201210419338A CN 102872110 A CN102872110 A CN 102872110A
- Authority
- CN
- China
- Prior art keywords
- houttuynoid
- breast cancer
- medicament
- mcf
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- ROCYDQPSKYPRJK-KXDBBDCJSA-N 2-[3,4-dihydroxy-2-(2-oxoundecyl)phenyl]-5,7-dihydroxy-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one Chemical compound CCCCCCCCCC(=O)CC1=C(O)C(O)=CC=C1C1=C(O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)C(=O)C2=C(O)C=C(O)C=C2O1 ROCYDQPSKYPRJK-KXDBBDCJSA-N 0.000 title claims abstract description 46
- 206010006187 Breast cancer Diseases 0.000 title claims abstract description 25
- 208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 25
- 239000003814 drug Substances 0.000 title claims abstract description 17
- 150000001875 compounds Chemical class 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 12
- 230000012010 growth Effects 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 6
- 230000005764 inhibitory process Effects 0.000 abstract description 3
- 238000011161 development Methods 0.000 abstract description 2
- -1 Methyl Thiazolyl Chemical group 0.000 abstract 1
- 238000002841 anti-cancer assay Methods 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 12
- 208000009889 Herpes Simplex Diseases 0.000 description 4
- 241000700584 Simplexvirus Species 0.000 description 4
- 230000003602 anti-herpes Effects 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 240000000691 Houttuynia cordata Species 0.000 description 3
- 235000013719 Houttuynia cordata Nutrition 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 229930190556 houttuynoid Natural products 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 0 CCCCCCCC(CC)OCc(c(O)c(cc1)O)c1C(Oc1cc(O)cc(O)c1C1=O)=C1OC(C1O)OC(C*)C(*)C1O Chemical compound CCCCCCCC(CC)OCc(c(O)c(cc1)O)c1C(Oc1cc(O)cc(O)c1C1=O)=C1OC(C1O)OC(C*)C(*)C1O 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了Houttuynoid D在制备治疗乳腺癌药物中的应用，属于药物新用途技术领域。本发明通过体外MTT抗肿瘤活性评价发现，Houttuynoid D对人乳腺癌细胞株4T1、MCF-7、MDA-MB-231和MCF-7B的生长也具有显著的抑制作用。因此，Houttuynoid D能用于制备抗乳腺癌药物，具有良好的开发应用前景。对于本发明涉及的Houttuynoid D在制备治疗乳腺癌药物中的用途属于首次公开，由于骨架类型属于全新的骨架类型，而且其对于乳腺癌细胞的抑制活性强得意想不到。
Description
技术领域
本发明涉及化合物Houttuynoid D的新用途，尤其涉及HouttuynoidD在制备抗乳腺癌药物中的应用。
技术背景
癌症是对人类生命健康危害最大的疾病之一，每年都有大量的人死于癌症。抗癌药物的研发一直是药学研究的热点。抗肿瘤药物中有74%是天然产物或其衍生物，如紫杉醇及其衍生物就是目前临床上应用效果比较好的抗肿瘤药物。因此，从天然产物中寻找抗癌化合物或先导化合物具有重要的意义。
本发明涉及的化合物Houttuynoid D是一个2012年发表（Chen, S.D. et al., 2012. Houttuynoid D_E, Anti-Herpes SimplexVirus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772–1775.）的新骨架化合物，该化合物拥有全新的骨架类型，目前的用途仅仅涉及抗单纯疱疹病毒活性（Chen, S. D. et al., 2012. Houttuynoid D_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772–1775.），对于本发明涉及的Houttuynoid D在制备治疗乳腺癌药物中的用途属于首次公开，由于骨架类型属于全新的骨架类型，而且其对于乳腺癌细胞的抑制活性强得意想不到，不存在由其他化合物给出任何启示的可能，具备突出的实质性特点，同时用于乳腺癌的防治显然具有显著的进步。
发明内容
本发明提供化合物Houttuynoid D在制备抗肿瘤药物中的应用。
本发明采用如下技术方案：Houttuynoid D在制备抗乳腺癌药物中的应用，Houttuynoid D的结构式如式（Ⅰ）所示：
式（Ⅰ）
本发明通过体外MTT抗肿瘤活性评价发现，Houttuynoid D对人乳腺癌细胞株4T1、MCF-7、MDA-MB-231和MCF-7B的生长也具有显著的抑制作用，抑制这4株细胞生长的IC50值分别为0.19±0.07μM、0.31±0.05μM、0.21±0.08μM和0.37±0.06μM。因此，Houttuynoid D能用于制备抗乳腺癌药物，具有良好的开发应用前景。
本发明涉及的Houttuynoid D在制备治疗乳腺癌药物中的用途属于首次公开，由于骨架类型属于全新的骨架类型，而且其对于乳腺癌细胞的抑制活性强得意想不到，不存在由其他化合物给出任何启示的可能，具备突出的实质性特点，同时用于乳腺癌的防治显然具有显著的进步。
以下通过实施例对本发明作进一步详细的说明，但本发明的保护范围不受具体实施例的任何限制，而是由权利要求加以限定。
具体实施方式
本发明所涉及化合物Houttuynoid D的制备方法参见文献（Chen, S. D. et al., 2012.Houttuynoid D_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata.Organic Letters 14 (7), 1772–1775.）。
以下通过实施例对本发明作进一步详细的说明，但本发明的保护范围不受具体实施例的任何限制，而是由权利要求加以限定。
实施例1：本发明所涉及化合物Houttuynoid D片剂的制备：
取20克化合物Houttuynoid D，加入制备片剂的常规辅料180克，混匀，常规压片机制成1000片。
实施例2：本发明所涉及化合物Houttuynoid D胶囊剂的制备：
取20克化合物Houttuynoid D，加入制备胶囊剂的常规辅料如淀粉180克，混匀，装胶囊制成1000片。
下面通过药效学实验来进一步说明其药物活性。
实验例：采用MTT法评价化合物Houttuynoid D对人乳腺癌细胞株的生长抑制作用
1．方法：处于生长对数期的细胞：人乳腺癌细胞株4T1、MCF-7、MDA-MB-231和MCF-7B（购买自中国科学院细胞库）以1.5×104浓度种于96孔板中。细胞培养24 h贴壁后吸去原来的培养基。试验分为空白对照组、药物处理组。空白组更换含10%胎牛血清的1640培养基；药物处理组更换含浓度为100 μM，50 μM，10 μM，1 μM，0.1 μM，0.01 μM和0.001 μM的Houttuynoid D的培养基。培养48 h后，加入浓度5 mg/mL的MTT，继续放于CO2培养箱培养4 h，然后沿着培养液上部吸去100 μL上清，加入100 μL DMSO，暗处放置10min，利用酶标仪（Sunrise公司产品）测定吸光值(波长570nm)，并根据吸光值计算细胞存活情况，每个处理设6个重复孔。细胞存活率(%)=ΔOD药物处理/ΔOD空白对照×100。
2. 结果：Houttuynoid D对人乳腺癌细胞株4T1、MCF-7、MDA-MB-231和MCF-7B的生长具有显著的抑制作用。该化合物抑制人乳腺癌细胞株4T1、MCF-7、MDA-MB-231和MCF-7B生长的IC50值分别为：0.19±0.07μM、0.31±0.05μM、0.21±0.08μM和0.37±0.06μM。
由上述实施例表明，本发明的Houttuynoid D对人乳腺癌细胞株4T1、MCF-7、MDA-MB-231和MCF-7B的生长具有很好的抑制作用。由此证明，本发明的Houttuynoid D具有抗乳腺癌活性，能用于制备抗乳腺癌药物。
Claims (1)
1.Houttuynoid D在治疗乳腺癌药物中的应用，所述化合物Houttuynoid D结构如式（Ⅰ）所示：
式（Ⅰ）。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210419338.1A CN102872110B (zh) | 2012-10-27 | 2012-10-27 | Houttuynoid D在制备治疗乳腺癌药物中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210419338.1A CN102872110B (zh) | 2012-10-27 | 2012-10-27 | Houttuynoid D在制备治疗乳腺癌药物中的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102872110A true CN102872110A (zh) | 2013-01-16 |
| CN102872110B CN102872110B (zh) | 2013-08-28 |
Family
ID=47473781
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210419338.1A Active CN102872110B (zh) | 2012-10-27 | 2012-10-27 | Houttuynoid D在制备治疗乳腺癌药物中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102872110B (zh) |
-
2012
- 2012-10-27 CN CN201210419338.1A patent/CN102872110B/zh active Active
Non-Patent Citations (1)
| Title |
|---|
| CHEN SD ET AL: "Houttuynoids A-E, anti-herpes simplex virus active flavonoids with novel skeletons from Houttuynia cordata", 《ORGANIC LETTERS》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102872110B (zh) | 2013-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102872089B (zh) | Houttuynoid E在制备治疗皮肤癌药物中的应用 | |
| CN102872110B (zh) | Houttuynoid D在制备治疗乳腺癌药物中的应用 | |
| CN102872121B (zh) | Houttuynoid C在治疗喉癌药物中的应用 | |
| CN102872112B (zh) | Houttuynoid A在制备治疗膀胱癌药物中的应用 | |
| CN102872123B (zh) | Houttuynoid C在治疗膀胱癌药物中的应用 | |
| CN102872075A (zh) | Houttuynoid E在治疗乳腺癌药物中的应用 | |
| CN102872134B (zh) | Houttuynoid D在治疗喉癌药物中的应用 | |
| CN102872109B (zh) | Houttuynoid A在制备治疗前列腺癌药物中的应用 | |
| CN102872125B (zh) | Houttuynoid C在治疗宫颈癌药物中的应用 | |
| CN102872137B (zh) | Houttuynoid B在制备治疗宫颈癌药物中的应用 | |
| CN102872144B (zh) | Houttuynoid D在制备治疗膀胱癌药物中的应用 | |
| CN102872085B (zh) | Houttuynoid A在治疗乳腺癌药物中的应用 | |
| CN102872139B (zh) | Houttuynoid C在治疗舌癌药物中的应用 | |
| CN102872070B (zh) | Houttuynoid C在治疗前列腺癌药物中的应用 | |
| CN102872142B (zh) | Houttuynoid D在制备治疗卵巢癌药物中的应用 | |
| CN102885843B (zh) | Houttuynoid B在治疗乳腺癌药物中的应用 | |
| CN102872135B (zh) | Houttuynoid D在治疗肾癌药物中的应用 | |
| CN102872086A (zh) | Houttuynoid A在治疗皮肤癌药物中的应用 | |
| CN102895224A (zh) | Aphanamixoid A在治疗乳腺癌药物中的应用 | |
| CN102872102A (zh) | Houttuynoid C在治疗乳腺癌药物中的应用 | |
| CN102895248A (zh) | Houttuynoid A在治疗喉癌药物中的应用 | |
| CN102872117A (zh) | Houttuynoid D在治疗胃癌药物中的应用 | |
| CN102872088A (zh) | Houttuynoid D在治疗鼻咽癌药物中的应用 | |
| CN102872151A (zh) | Houttuynoid B在治疗鼻咽癌药物中的应用 | |
| CN102872111A (zh) | Houttuynoid C在治疗胰腺癌药物中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: RUDONG TECHNOLOGY CENTER Free format text: FORMER OWNER: NANJING UNIVERSITY Effective date: 20141226 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 210093 NANJING, JIANGSU PROVINCE TO: 226400 NANTONG, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20141226 Address after: 226400 No. 66 Youyi West Road, dug Town, Rudong County, Jiangsu, Nantong Patentee after: Rudong science and Technology Center Address before: 210093 Nanjing, Gulou District, Jiangsu, No. 22 Hankou Road Patentee before: Nanjing University |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20200420 Address after: No. 10, Fandi South Road, juegang Town, Rudong County, Nantong City, Jiangsu Province Patentee after: Rudong industrial and commercial information consulting service center Address before: 226400 No. 66 Youyi West Road, dug Town, Rudong County, Jiangsu, Nantong Patentee before: Rudong science and Technology Center |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20211220 Address after: Fengli town Xinjian West Road, Rudong County, Nantong City, Jiangsu Province 226400 Patentee after: Rudong Wenyuan investment and Development Co., Ltd Address before: 226400 No.10 Fandi South Road, juegang Town, Rudong County, Nantong City, Jiangsu Province Patentee before: Rudong industrial and commercial information consulting service center |
|
| TR01 | Transfer of patent right |